China moves AI brain implants from trials towards real-world use

Chinese firms are accelerating the transition of AI-driven brain-computer interfaces (BCIs) from clinical trials to real-world applications. Companies like NeuroXess in Shanghai have conducted small-scale trials, including a 2024 test where a 28-year-old man with a spinal cord injury used a skull-mounted implant to control appliances via thought. The system connects to a chest-mounted transmitter and leverages a large-language model to decode Mandarin at 300 characters per minute—faster than natural speech—while generating words for a 35-year-old woman with epilepsy. The Chinese government has set ambitious goals, targeting major BCI breakthroughs by 2027 and establishing two or three world-class firms by the end of the decade. In March 2024, China approved the world’s first commercial brain implant, marking a milestone in neurotechnology. However, rapid advancements have raised privacy concerns, prompting the government to release 2024 ethical guidelines requiring participant consent and ethics assessments for trials. NeuroXess’s co-founder, Tiger Tao, noted that the Chinese public is more accepting of data-sharing for technological progress, creating a feedback loop where improved AI models boost user confidence. Meanwhile, U.S.-based competitors like Neuralink have faced stricter regulatory scrutiny, though both regions are competing to dominate the BCI market. The Chinese approach balances innovation with regulatory oversight, aiming to balance ethical standards with rapid commercialization.